MaxCyte (MXCT) has released an update.
MaxCyte, Inc., a leader in cell-engineering technologies, announced that John Johnston, a Non-Executive Director, has exercised options to acquire 3,000 shares and subsequently sold them on the Nasdaq stock exchange at prices ranging from $3.70 to $3.74. This transaction involved less than 1% of Johnston’s total holdings in the company, leaving him with over 120,000 shares and a significant number of options and restricted stock units. Investors may find this activity indicative of strategic portfolio adjustments by company insiders.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
